Malignant pleural mesothelioma
asbestos malignancy · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Mesothelioma is an aggressive pleural malignancy strongly linked to prior asbestos exposure, presenting with breathlessness, chest pain and pleural effusion. Prognosis is poor; management is largely palliative with a growing role for immunotherapy and symptom-directed pleural intervention.
Red flags
- Rapidly reaccumulating effusion with breathlessness
- Severe refractory chest-wall pain
- Superior vena cava obstruction / chest-wall invasion
- Weight loss and declining performance status
Assessment
Differential diagnosis
- Metastatic pleural malignancy (lung, breast)
- Benign asbestos-related pleural disease
- Pleural tuberculosis
- Empyema
- Lymphoma
- Fibrous tumour of the pleura
Investigations
- Contrast CT chest (pleural thickening, nodularity, effusion, mediastinal involvement)
- Pleural fluid cytology (often low yield)
- Image-guided or thoracoscopic pleural biopsy with immunohistochemistry (definitive)
- PET-CT for staging
- Lung function and performance-status assessment
- Detailed asbestos-exposure/occupational history
Management
- Take a detailed asbestos-exposure history and document for medicolegal purposes
- Image with CT and assess pleural thickening and effusion
- Obtain definitive histology via thoracoscopic or image-guided biopsy (cytology alone is unreliable)
- Determine histological subtype (epithelioid better prognosis than sarcomatoid)
- Stage with PET-CT and assess fitness/performance status
- Discuss at a thoracic MDT including options and prognosis
- Control the pleural effusion with talc pleurodesis or an indwelling pleural catheter
- Offer systemic therapy — immunotherapy combination or platinum-pemetrexed chemotherapy
- Consider trimodality/surgery only in highly selected epithelioid cases at specialist centres
- Integrate early palliative care, symptom control and compensation/benefits advice
Drugs & doses
Nivolumab + ipilimumab immunotherapy combination (first-line for many)
Cisplatin 75 mg/m2 IV + pemetrexed 500 mg/m2 IV every 3 weeks (with B12/folate) chemotherapy
Talc 4-5 g for pleurodesis
Opioids and neuropathic agents for chest-wall pain
Disposition
Thoracic MDT / specialist mesothelioma centre; early palliative care; medicolegal and benefits support.
Complications & pitfalls
- Trapped lung and refractory effusion
- Chest-wall pain and invasion
- Cachexia
- Disease progression despite therapy
Exam pearls
- Cytology alone is often insufficient — pursue a tissue biopsy for diagnosis and subtype
- Avoid multiple drain sites; procedure-tract metastasis can occur (though routine prophylactic radiotherapy is no longer standard)
- Epithelioid subtype has markedly better prognosis than sarcomatoid
- Always document asbestos exposure — patients may be entitled to compensation
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.